Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like Vancouver???s Zymeworks to Hire an Additional 45 Employees by the End of 2017 May 30, 2017 6 Blood Testing Startups Hoping to be The Next Theranos – The Good Version January 11, 2018 4C Medical Tech Exceeds $8 Million Convertible Note Financing Round Led By July 18, 2017